Search

everythinglearnresearchcommunity

for

Search:↓

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Ixekizumab effectively treats generalized pustular psoriasis.

The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.

Men with a certain type of hair loss often use facial moisturizers, and a specific antibiotic treatment may help another hair condition.

Mogamulizumab can cause hair loss and skin rashes.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

Promising cancer treatments were found, but the manufacturer closed.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

A medication for skin rash also unexpectedly treated hair loss in a patient.

Abrocitinib may effectively treat Lichen Planopilaris.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Rezpegaldesleukin shows promise for treating severe alopecia areata.

Nail changes from immunotherapy can be managed without stopping cancer treatment.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.

Dermatologists are crucial for managing skin side effects in metastatic melanoma patients using vemurafenib and ipilimumab.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Eculizumab helps reduce blood transfusions and stabilize hemoglobin but increases infection risk and is expensive.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Ocrelizumab may cause pancreatitis in some patients.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.

Biological therapy boosts the immune system to effectively fight melanoma.

Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.

Anifrolumab treatment improves quality of life and reduces disease activity and steroid use in SLE patients.

A woman with advanced eye cancer went into complete remission using a combination of immunotherapy and topical treatments.